Current Hematologic Malignancy Reports

, Volume 9, Issue 2, pp 186–192

Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

Authors

  • Amir T. Fathi
    • Center for LeukemiaMassachusetts General Hospital
    • Bone Marrow Transplant Unit, Cox 108Massachusetts General Hospital
Acute Leukemias (R Stone, Section Editor)

DOI: 10.1007/s11899-014-0209-2

Cite this article as:
Fathi, A.T. & Chen, Y. Curr Hematol Malig Rep (2014) 9: 186. doi:10.1007/s11899-014-0209-2

Abstract

Disease relapse remains a major cause of mortality for patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Historically, patients who experience disease relapse after HSCT have a dismal prognosis with very few long-term survivors. There is no standard treatment for patients in this situation given the variability in patient characteristics, disease biology, complications such as graft-vs.-host disease (GVHD) and infections, donor availability, and patient choice. Here, we discuss the current options for treatment of relapsed AML after HSCT including conventional chemotherapy, novel agents, donor leukocyte infusion, second allogeneic HSCT, and emerging therapies.

Keywords

Acute myeloid leukemia Allogeneic hematopoietic stem cell transplantation Relapse Graft-vs.-host disease (GVHD) Emerging therapies

Copyright information

© Springer Science+Business Media New York 2014